Top Menu

Navigation

Speaker Fees

By on November 18, 2020 in Compliance, Healthcare Providers As Foreign Officials, Medical Device Industry, Pharmaceutical Industry, Speaker Fees
Speaking3

Numerous Foreign Corrupt Practices Act enforcement actions have involved the enforcement theory that various foreign health care professionals (HCP’s) are “foreign officials” and thus occupy a status similar to a President, Prime Minister, or other traditional bona fide government official.

Several of these enforcement actions have included allegations that HCP’s received speaker fees or honoraria from pharmaceutical or medical device companies.

For instance, the Sanofi enforcement action included allegations that an HCP was provided “with consulting, speaking, and clinical trial fees over a period of years despite the lack of documentation or other support to demonstrate the services had been provided.”

Continue Reading

Potpourri

By on November 17, 2020 in Canada, Compliance, Damodar Arapakota, Greens, IMEX Systems, Och-Ziff Capital, Och-Ziff Capital Management, Siriwan, Victims
Potpourri

[To the best of my recollection, my first introduction to the word “potpourri” was in watching Jeopardy which I was very fond of as a teenager and young adult. Rest in peace Alex Trebek]

Lingo

Daniel Kahn (Acting Chief of the DOJ Fraud Section) was the guest on this recent episode of the Compliance Perspectives Podcast. During the podcast, Kahn talks about COVID’s impact on DOJ enforcement and certain recent enforcement actions such as Goldman Sachs and Beam.

In terms of the DOJ’s mid-2000 revision to its “Evaluation of Corporate Compliance Programs” policy document, Kahn stated that it certainly is by no means a “game changer.” Call me old-fashioned, but I want to hear the DOJ Fraud Section Chief talk about the law and legal requirements not lingo. Yet, the podcast dishes up plenty of lingo (tone at the top, conduct at the top, tone of upper and middle management, empowering compliance, walking the walk, direct line to the board, dotted line to the board, etc.).

Continue Reading

The FCPA Doesn’t Answer Many Of The Questions Compliance Professionals Have

By on November 13, 2020 in Compliance, Internal Controls
confusion

Naturally, and understandably, those tasked with Foreign Corrupt Practices Act compliance within a business organization want clear answers to many questions.

However, the FCPA rarely provides clear answers and this is particularly true with the internal controls provisions.

The provisions are not rule-based, but principle-based in the sense that the key statutory language is that issuers  shall “devise and maintain a system of internal accounting controls sufficient to provide reasonable assurances” certain financial objectives are met. The FCPA then defines  “reasonable assurances” to mean “such level of detail and degree of assurance as would satisfy prudent officials in the conduct of their own affairs.”

Continue Reading

Goldman – What Should Happen When Compliance Is Decent (And Often Good), But Not Great?

By on October 27, 2020 in Compliance, Goldman Sachs, Internal Controls
question marks2

The recent Foreign Corrupt Practices Act enforcement action against Goldman Sachs was the largest in FCPA history in terms of actual settlement amount ($1.66 billion).

Yes, the conduct at issue involved large bribe payments (according to the DOJ approximately $1.6 billion). Yes, the conduct at issue resulted in (according to the DOJ) Goldman obtaining “in excess of $600 million in fees and revenue across its divisions, and increased Goldman’s stature in SE Asia.” Yes, the conduct of the culpable Goldman employees criminally charged (Tim Leissner and Roger Ng) was egregious.

Viewed through the strict lens of respondeant superior, perhaps the record-setting FCPA enforcement action was justified. In this regard, the Goldman press release nicely stated in plain English: “We all share in the benefits when our colleagues perform well for our clients. The opposite must be true as well.  When a colleague knowingly violates a firm policy, or much worse, the law, we – as a firm – have to accept responsibility and recognize the broader failure that individual behavior represents for our firm.”

However, based on the DOJ’s (and SEC’s) allegations, the Goldman enforcement action was much different than certain other top ten FCPA enforcement actions.

Continue Reading

Friday Roundup

By on October 16, 2020 in Compliance, FCPA Appeals, FCPA Sentences, Jesus Ramon Veroes, Lawrence Hoskins, Luis Alberto Chacin Haddad
Roundup

Checking in on an appeal, sentence reduced, and for the reading stack. It’s all here in the Friday roundup.

Checking In On An Appeal

This recent post highlighted the DOJ’s appeal in the Lawrence Hoskins matter.

Recently Hoskins filed a brief in response and is also cross-appealing certain issues.

As to the DOJ’s appeal challenging the trial court’s decision to acquit Hoskins of all FCPA charges on the grounds that the trial evidence utterly failed to prove he acted as an agent of a domestic concern, the brief states in summary fashion:

Continue Reading

Powered by WordPress. Designed by WooThemes